SYNCAR 001
Alternative Names: Orthogonal IL-2 receptor-modified CD-19 targeted CAR-T - Synthekine; STK 009/SYNCAR 001; STK-009 + SYNCAR-001; SYNCAR-001Latest Information Update: 28 Mar 2024
At a glance
- Originator Synthekine
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies
- Preclinical Cancer; Lymphoma
Most Recent Events
- 26 Mar 2024 The US FDA clears an IND application to initiate a combination trial for Systemic lupus erythematosus and lupus nephritis
- 26 Mar 2024 Synthekine plans a phase II trial for Systemic lupus erythematosus (SLE) and Lupus nephritis (Combination therapy) in the second half of 2024
- 31 Dec 2022 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT05665062)